Regeneron is buying 23andMe for $256M in bankruptcy, gaining access to DNA data from 15 million users to aid drug research.

What happened to 23andMe? Here's a look at its history from launch to bankruptcy and acquisition by Regeneron.

On Monday, Regeneron Pharmaceuticals announced that it would acquire most of 23andMe's assets for $256 million. According to ...

Regeneron is buying the assets of 23andMe, which filed for Chapter 11 bankruptcy in March after facing a series of hurdles ...

Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe for $256 million through a bankruptcy auction, the ...

Regeneron Pharmaceuticals said it would acquire 23andMe, which filed for bankruptcy in March and would continue to offer ...

The DNA testing firm 23andMe says it has entered into an agreement to be acquired by Regeneron Pharmaceuticals for $256m ...

Genetic testing company 23andMe isn’t going away, despite declaring bankruptcy. The company and nearly all of its assets, ...

Bankrupt genetic-testing firm 23andMe agreed to sell its data bank, which once contained DNA samples from about 15 million ...

The top bidder in the DNA testing firm's bankruptcy auction, Regeneron vows to prioritize the privacy, security, and ethical ...

Regeneron Pharmaceuticals said on Monday it will buy genetic testing firm 23andMe Holding for $256 million through a ...

The deal would put the DNA data of millions of customers in the hands of a pharmaceutical company, which hopes to supercharge ...